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CLINICAL AND ECONOMIC CONSEQUENCES OF MEDICATION NON-
ADHERENCE IN THE TREATMENT OF PATIENTS WITH A MANIC/
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EUROPEAN MANIA IN BIPOLAR LONGITUDINAL EVALUATION OF 
MEDICATION (EMBLEM) STUDY
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1London School of Economics, London, UK, 2Eli Lilly and Company, Windlesham, Surrey, 
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OBJECTIVES: To investigate the consequences of medication non-adherence on 
relapse, recurrence, remission and recovery, and to estimate costs associated with 
non-adherence over 21-months in the treatment of bipolar disorder following a manic 
or mixed episode. METHODS: EMBLEM is a prospective, observational study on 
patient outcomes with a manic/mixed episode. Data was collected at baseline, during 
the ﬁrst 12 weeks of treatment (acute phase), at 6 month post-baseline and at 6-month 
intervals up to 24 months (maintenance phase). Medication adherence was assessed 
at each visit by investigators as: i) not prescribed medication; ii) almost always adheres; 
iii) adheres half of the time; and iv) never adheres to medication. Adherence was 
deﬁned as always answering ‘always adheres’ and non-adherence was deﬁned when 
one or more response of ‘adheres half of the time’ or ‘never adheres’. In this post-hoc 
analysis, Cox proportional hazards models with non-adherence, adjusted for patient 
characteristics, investigated its impact on clinical outcomes. Multivariate analyses were 
performed to estimate the cost of resource use associated with non-adherence during 
the maintenance phase, using a log-link function. UK unit costs were applied to 
resource use. RESULTS: Of the 1341 patients analysed, 23.6% were non-adherent 
over 21-months. Non-adherence was signiﬁcantly associated with a higher risk of 
relapse (HR:2.40, 95%CI:2.04–2.83) and recurrence (HR:1.72, 95%CI:1.27–2.33) as 
well as lower remission rates (Hazard ratio (HR):0.71, 95%CI:0.59–0.86) and recov-
ery (HR:0.65, 95%CI:0.51–0.81). In addition, costs incurred by non-adherent patients 
during this period were signiﬁcantly higher than those of adherent patients (£10231 
vs. £7379). This disparity resulted mainly from differences in in-patient costs (£4796 
vs. £2150). CONCLUSIONS: Non-adherence in bipolar patients after a manic/mixed 
episode is associated with higher than twice the risk of relapse of adherent patients 
which has economic implications for health care providers. A study limitation is that 
adherence was assessed by investigators using a single-item measure.
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OBJECTIVES: To compare treatment patterns and health care costs among subjects         
newly treated with donepezil versus subjects newly treated with rivastigmine or galan-     
tamine. METHODS: This retrospective claims-based analysis utilized data from a 
large US managed care plan. Subjects were q50 years of age; ﬁlled q1 prescription 
for donepezil, rivastigmine, or galantamine from January 1, 2005–December 31, 2007; 
and were continuously enrolled for q18 months. Rivastigmine and galantamine 
cohorts were each matched to donepezil cohort at 1:3 ratio by propensity score. 
Logistic regression, Cox regression, and generalized linear models with gamma distri-
bution and log link were used to examine adherence (medication possession ratio 
q80%), persistence/discontinuation and total health care costs, as appropriate. 
RESULTS: Of 488 rivastigmine subjects, 33.0% were adherent and 69.3% discontin-
ued medication while the rates of adherence and discontinuation in the matched 1,464 
donepezil users were 42.4% and 60.7%, respectively. Compared with rivastigmine 
cohort, donepezil subjects were more likely to be adherent (OR: 1.395, 95% CI: 
1.117–1.742, p  0.003) and had a lower risk of discontinuation (RR: 0.827, 95% 
CI: 0.729–0.939, p  0.003). Mean annualized total health care costs did not 
differ signiﬁcantly between two cohorts (donepezil: $11,431; rivastigmine: $12,358), 
although donepezil appeared to be associated with lower costs in regression analysis 
(Cost Ratio: 0.898, 95% CI: 0.803–1.005, p  0.06). Of 597 galantamine subjects, 
36.5% were adherent and 65.7% discontinued medication while the rates of adher-
ence and discontinuation in the matched 1,791 donepezil users were 42.0% and 
60.6%, respectively. Donepezil users were more likely to be adherent than galantamine 
users (OR: 1.261, 95% CI: 1.038–1.534, p  0.020); however, discontinuation 
risk was similar. Annualized health care costs were similar in the two cohorts both 
bivariately (donepezil: $11,644; galantamine:$ 10,876) and in regression analysis. 
CONCLUSIONS: Donepezil users demonstrated better adherence than each of the 
matched cohorts, and lower discontinuation risk than the rivastigmine cohort. Total 
costs were similar.
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OBJECTIVES: Cost analysis of different dementia screening tests available in Spain 
from the health care system perspective. METHODS: A number of screening tests for 
General Practitioner (GP) consultation have been compared. According to their dura-
tion they were classiﬁed in long (5 minutes) and short (5 minutes) tests. The long 
tools evaluated were Mini-Mental State Examination (MMSE), a Spanish validated 
adaptation of MMSE (MEC-30), Eurotest and Memory Alteration Test (T@M). On 
the other hand, short tools evaluated were Fototest, Semantic Verbal Fluency (SVF), 
Memory Impairment Screen (MIS), Clock test (CT) and Short Portable Mental Status 
Questionnaire (SPMSQ) or Pfeiffer Test. Direct costs of the screening and the costs 
of veriﬁcation at hospital of the preliminary diagnosis were calculated. Costs by 
correct diagnosis (TP) have been calculated based on public prices of GP’s consulta-
tions and on analytical accounting of the public University Hospital Hospital Virgen 
de las Nieves (Granada, Spain). RESULTS: Total cost of each screening test was cal-
culated as the addition of the GP study for each patient (long screening a64.4a and 
short screening a43.5) plus the cost of the speciﬁc study for conﬁrmation at hospital 
for positive diagnosis (laboratory tests a123.61 and medical consultations a208.86 
per patient). Lower cost tests are Fototest (a527 per TP) and SPMSQ (a545.2 per TP). 
The rest of evaluated tests have higher costs (10–20%: CT, FVS, MEC-30 and 
Eurotest; 20–30%: MIS and T@M; 60%: MMSE). CONCLUSIONS: The MMSE, 
the most used screening test, is the most expensive. Fototest and SPMSQ are the 
screening test of lowest cost. Both tests are short, applicable to illiterates and show 
the same effectiveness as long tools. According to previous results, it may be recom-
mendable to take into account the differences among tests in terms of opportunity 
costs and potential budgetary impact, in the design of a broad regional screening 
dementia strategy.
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OBJECTIVES: Our recent study showed that multiple factors including patient 
characteristics, comorbidities, prior medications, prior health care utilization and 
costs were associated with initial prescription dosage of duloxetine in the treatment 
of major depressive disorder (MDD). The purpose of the present study was to 
examine the associations between initial prescription dosage of duloxetine and 
hospitalization and costs in the 1-year follow-up period. METHODS: Of 10,128 
patients with MDD in a large commercial administrative claims database who 
were initiated on duloxetine between July 1, 2005 and June 30, 2006 and had no 
prescriptions of duloxetine in the prior 6 months, 6132 (60.5%) had continuous 
enrollment for 12 months prior to and post-duloxetine initiation. According to 
initial prescription dose, patients were divided into 3 cohorts: low-dose (60 mg/day, 
n  1,989), mid-dose (60 mg/day, n  3,733), and high-dose (60 mg/day, n  410). 
Intent-to-treat analysis was conducted to compare health care utilization and costs in 
the 1 year prior and post-initiation across the 3 cohorts. RESULTS: During the post 
1 year, hospitalization rate was signiﬁcantly reduced by 5.7% for mid-dose cohort (p 
 0.001), 6.9% for high-dose cohort (p  0.05), and 7.3% for low-dose cohort (p  
0.001). Pharmacy costs in the post 1 year increased in all 3 cohorts: low-dose, $672 
(p  0.001); mid-dose, $825 (p  0.001); and high-dose, $1437 (p  0.05). However, 
mean medical costs declined in high-dose patients ($2617) and mid-dose patients 
($340), but increased in low-dose patients ($261). Mean total health care costs 
numerically declined by $1,180 ($20,225-$21,406) in high-dose patients, but increased 
in low-dose patients by $933 ($18,002–$17,069) and mid-dose patients by $485 
($16,917-$16,432), although these cost changes were not signiﬁcant. CONCLU-
SIONS: The hospitalization rate was signiﬁcantly reduced in all patients after dulox-
etine initiation. Although pharmacy costs increased more in high-dose patients than 
in mid- and low-dose patients; the higher medication costs were offset by lower 
medical costs.
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DIFFERENCES IN HEALTH CARE USES AFTER TREATMENT OF 
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OBJECTIVES: This retrospective study aimed to compare health care utilization 
associated with duloxetine versus other antidepressants for patients with major depres-
sive disorder (MDD) in the Veterans Affairs (VA) health system. Duloxetine was not 
on the VA national drug formulary. METHODS: The electronic medical records 
from October 2004 to October 2008 were extracted from the VA Veterans Integrated 
Service Network 16 data warehouse. All patients were treated with either duloxetine 
monotherapy or other antidepressants (non-duloxetine) over the study period. 
The ﬁrst dispense date of the index agent was deﬁned as the index date. All patients 
